In stock
FOX04-DRI 10MG
$184.00
-
This product is intended for laboratory research use only.
-
Not for human or veterinary use.
-
Not approved for diagnostic, therapeutic, or medical applications.
-
Handle using appropriate laboratory safety procedures and personal protective equipment.
Description
DESCRIPTION
FOXO4-DRI is a synthetic D-retro-inverso peptide designed to disrupt the FOXO4–p53 interaction. It is studied for its senolytic properties — selectively targeting senescent cells — with the aim of supporting tissue regeneration, organ health, and longevity research.
BENEFITS
- Cellular renewal — studied for selectively clearing senescent ‘zombie’ cells in models.
- Tissue rejuvenation — linked to improved organ function and resilience in aging research.
- Longevity science — explored for its role in lifespan and healthspan extension studies.
- Skin and hair health — animal data show improved coat condition after senescent cell clearance.
- Joint and cartilage support — lab studies suggest selective removal of senescent chondrocytes.
WHAT RESEARCHERS LOOK AT
- Mechanism: blocks FOXO4–p53 binding, triggering apoptosis in senescent cells.
- Animal models: improved kidney function, fur density, and activity levels in aged mice.
- Molecular effects: reduction of p16 and IL-6 markers tied to cellular senescence.
- Structural biology: evidence for targeting the p53 transactivation domain surface.
QUICK SPECS
- Form: Lyophilized peptide
- Net per vial: 10 mg
- Purity: ≥99% (HPLC)
- Identity: MS-verified (per COA)
- Storage: 2–8 °C, protect from light
IDENTITY BASICS
- Type: D-retro-inverso peptide (FOXO4-derived)
- Sequence: LTLRKEPASEIAQSILEAYSQNGWANRRSGGKRP (all D-amino acids, retro-inverso)
- Formula / M.W.: ~C228H388N86O64, ~5358 g/mol
- CAS: 2460055-10-9
SELECTED RESEARCH
- Cell (2017) — FOXO4-DRI senolytic mouse study:
https://pmc.ncbi.nlm.nih.gov/articles/PMC5556182/
- Frontiers in Bioengineering & Biotechnology (2021) — selective removal of senescent chondrocytes:
https://www.frontiersin.org/articles/10.3389/fbioe.2021.677576/full
- Nature Communications (2025) — p53 transactivation domain target study:
https://www.nature.com/articles/s41467-025-60844-9
⚠️ DISCLAIMER
-
This product is intended for laboratory research use only.
-
Not for human or veterinary use.
-
Not approved for diagnostic, therapeutic, or medical applications.
-
Handle using appropriate laboratory safety procedures and personal protective equipment.

